Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 412,612 | 398,237 | 361,426 | 327,026 | 352,299 |
| Receivables | 264,926 | 279,011 | 304,433 | 267,837 | 206,442 |
| Inventories | 81,404 | 121,058 | 152,772 | 161,283 | 146,362 |
| Other current assets | 0 | 11,782 | 12,372 | 12,119 | 22,408 |
| TOTAL | $788,954 | $833,897 | $859,974 | $811,428 | $766,331 |
| Non-Current Assets | |||||
| PPE Net | 2,952 | 3,379 | 3,836 | 4,195 | 4,345 |
| Other Non-Current Assets | 93,145 | 64,590 | 40,672 | 16,307 | 18,054 |
| TOTAL | $96,097 | $67,969 | $44,508 | $20,502 | $22,399 |
| Total Assets | $885,051 | $901,866 | $904,482 | $831,930 | $788,730 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 38,572 | 42,730 | 38,270 | 26,788 | 37,516 |
| Accrued Expenses | 140,184 | 139,835 | 122,781 | 101,399 | 127,806 |
| Other current liabilities | N/A | N/A | N/A | 77,287 | 75,830 |
| TOTAL | $185,509 | $191,260 | $169,168 | $215,291 | $247,593 |
| Non-Current Liabilities | |||||
| Long Term Debt | 359,489 | 358,982 | 364,025 | N/A | N/A |
| Deferred Revenues | N/A | 1,903 | 1,903 | 3,560 | N/A |
| Other Non-Current Liabilities | 111,514 | 114,503 | 106,962 | 349,963 | 346,616 |
| TOTAL | $471,003 | $473,485 | $470,987 | $349,963 | $346,616 |
| Total Liabilities | $656,512 | $664,745 | $640,155 | $565,254 | $594,209 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 125,516 | 124,393 | 121,766 | 121,366 | 120,582 |
| Common Shares | 12 | 12 | 12 | 12 | 12 |
| Retained earnings | -3,035,366 | -2,999,013 | -2,941,568 | -2,903,911 | -2,837,488 |
| Other shareholders' equity | -3,308 | -3,140 | -3,362 | -3,525 | -3,542 |
| TOTAL | $228,539 | $237,121 | $264,327 | $266,676 | $194,521 |
| Total Liabilities And Equity | $885,051 | $901,866 | $904,482 | $831,930 | $788,730 |